MX2016005955A - Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. - Google Patents

Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.

Info

Publication number
MX2016005955A
MX2016005955A MX2016005955A MX2016005955A MX2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A MX 2016005955 A MX2016005955 A MX 2016005955A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
hyperkalemia
zirconium silicate
microporous zirconium
Prior art date
Application number
MX2016005955A
Other languages
English (en)
Inventor
Jeffrey Keyser Donald
F Guillem Alvaro
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of MX2016005955A publication Critical patent/MX2016005955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a nuevas composiciones de silicato de zirconio microporoso que están formuladas para eliminar las toxinas, por ejemplo, iones potasio, del tracto gastrointestinal a una velocidad elevada sin causar efectos secundarios indeseables. Las formulaciones preferidas están diseñadas para evitar un aumento en pH de la orina en los pacientes y/o para evitar la posible entrada de partículas en el torrente sanguíneo del paciente. También se describe un método para preparar cristales de ZS-9 de alta pureza que exhiben un mayor nivel de capacidad de intercambio de potasio. Estas composiciones son particularmente útiles en el tratamiento terapéutico de hiperpotasemia. Estas composiciones también son útiles en el tratamiento de la enfermedad renal crónica, enfermedad vascular coronaria, diabetes mellitus y el rechazo de trasplantes.
MX2016005955A 2013-11-08 2014-11-07 Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia. MX2016005955A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361901886P 2013-11-08 2013-11-08
US201361914354P 2013-12-10 2013-12-10
US201461930328P 2014-01-22 2014-01-22
US201461930336P 2014-01-22 2014-01-22
US201462005484P 2014-05-30 2014-05-30
US201462015215P 2014-06-20 2014-06-20
PCT/US2014/064542 WO2015070015A1 (en) 2013-11-08 2014-11-07 Microporous zirconium silicate for the treatment of hyperkalemia

Publications (1)

Publication Number Publication Date
MX2016005955A true MX2016005955A (es) 2016-12-02

Family

ID=53042123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005955A MX2016005955A (es) 2013-11-08 2014-11-07 Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.

Country Status (13)

Country Link
US (2) US20160271174A1 (es)
EP (1) EP3065709A4 (es)
JP (1) JP2016535749A (es)
KR (1) KR20160110356A (es)
CN (1) CN106385795A (es)
AU (1) AU2014346572A1 (es)
CA (1) CA2929956A1 (es)
CL (1) CL2016001094A1 (es)
IL (1) IL245525A0 (es)
MX (1) MX2016005955A (es)
PH (1) PH12016500861A1 (es)
TW (1) TW201607544A (es)
WO (1) WO2015070015A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03294B (me) 2011-02-11 2019-07-20 Zs Pharma Inc Primena cirkonijum silikata za tretman hiperkalemije
JP2019108282A (ja) * 2017-12-15 2019-07-04 学校法人 久留米大学 体内カリウム値の調整剤
KR20210137154A (ko) * 2019-03-13 2021-11-17 아스트라제네카 아베 혈액투석 환자에서의 사용을 위한 칼륨-결합제
US11577014B2 (en) 2019-07-09 2023-02-14 Uop Llc Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
US11964266B2 (en) 2019-07-09 2024-04-23 Uop Llc Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) 2019-07-09 2022-11-01 Uop Llc Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
WO2021199239A1 (ja) * 2020-03-31 2021-10-07 興和株式会社 包装体入り含水組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
US6804800B2 (en) * 2000-12-29 2004-10-12 Intel Corporation Method and apparatus for detecting and recovering from errors in a source synchronous bus
JP2004075612A (ja) * 2002-08-19 2004-03-11 National Agriculture & Bio-Oriented Research Organization 免疫機能増強剤
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
EP2367499A2 (en) * 2008-12-12 2011-09-28 Forsyth Dental Infirmary for Children Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy
EP2440210A4 (en) * 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
ME03294B (me) * 2011-02-11 2019-07-20 Zs Pharma Inc Primena cirkonijum silikata za tretman hiperkalemije
WO2013040082A2 (en) * 2011-09-12 2013-03-21 Medtronic, Inc. Polystyrene sulfonate resin for use with a hemodialysis system having a controlled compliance dialysis circuit

Also Published As

Publication number Publication date
US20160375054A1 (en) 2016-12-29
CL2016001094A1 (es) 2016-11-11
JP2016535749A (ja) 2016-11-17
EP3065709A1 (en) 2016-09-14
KR20160110356A (ko) 2016-09-21
EP3065709A4 (en) 2017-06-14
PH12016500861A1 (en) 2016-07-18
WO2015070015A1 (en) 2015-05-14
CA2929956A1 (en) 2015-05-14
US20160271174A1 (en) 2016-09-22
TW201607544A (zh) 2016-03-01
CN106385795A (zh) 2017-02-08
AU2014346572A1 (en) 2016-06-09
IL245525A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2016204124A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
PH12016500861A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
PH12015500849A1 (en) Microporous zirconium silicate for treating hyperkalemia
PH12016500864A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia
MX2021012669A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
WO2014011876A3 (en) Zirconium silicate for treatment of hyperkalemia
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
EA201270575A1 (ru) Соединения
TW200616968A (en) Compound having basic substituent and application thereof
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX2010005018A (es) Tratamiento de complicaciones de nacimiento prematuro.
NO20064659L (no) Nye kvarterniserte quinuklidin-estere
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
NO20076557L (no) Tiazolderivater og anvendelse derav
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
NO20076559L (no) Tiazolderivater og anvendelse derav
EA201490795A1 (ru) 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции
MA38169A1 (fr) Ciclésonide pour le traitement d'une maladie des voies respiratoires chez les chevaux
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
WO2011089576A3 (en) Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad)
NZ624714A (en) Methods for treating gout in patient subpopulations
PH12016501119A1 (en) Zirconium silicate for treating hyperkalemia without co-administering lithium
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
EA201692549A1 (ru) Безводная кристаллическая форма свободного основания 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола